Immunovant (IMVT) Proxy filing summary

Executive summary

• Annual Meeting scheduled for September 2, 2026, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.

• Three director nominees (Jacob Bauer, Douglas Hughes, Robert Susman) are up for election to serve until 2027.

• Ernst & Young LLP proposed for ratification as independent auditor for fiscal year ending March 31, 2027.

• Advisory vote on executive compensation (say-on-pay) to be held, with annual frequency.

• Company advanced clinical development of IMVT-1402 and completed a $550 million capital raise in FY2026.

Voting matters and shareholder proposals

• Proposals include election of three directors, ratification of auditor, and advisory approval of executive compensation.

• Board recommends voting in favor of all proposals.

• Shareholders may submit proposals for the 2027 meeting between May 5 and June 4, 2027.

Board of directors and corporate governance

• Board consists of seven members; four elected by Series A preferred stockholder (RSL), three by common and preferred stockholders.

• Controlled company status under Nasdaq rules; not required to have a majority of independent directors.

• Audit, Compensation, and Nominating & Corporate Governance Committees are in place, with independent directors on the Audit Committee.

• Board met six times in FY2026; all directors attended at least 75% of meetings.

• Code of Business Conduct and Ethics and Corporate Governance Guidelines adopted.